ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,061 to 1,080 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Patients Receiving cCTA and FFRCT >0.80 vs Patients Receiving cCTA and FFRCT≤0.80: serious adverse events12 of 4,737

43 of 4,737

-0.7 points

-1.0 to -0.4

9,474NCT02499679

Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care

Albiglutide vs Placebo: deaths from any cause196 of 4,731

205 of 4,732

-0.2 points

-1.0 to 0.6

9,463NCT02465515

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Albiglutide vs Placebo: Number of Participants With Non-fatal Serious Adverse Events (SAEs)891 of 4,717

974 of 4,715

-1.8 points

-3.4 to -0.2

9,432NCT02465515

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Albiglutide vs Placebo: Number of Participants With Adverse Events (AEs) Leading to Discontinuation of Investigational Product (AELD)427 of 4,717

334 of 4,715

2.0 points

0.9 to 3.1

9,432NCT02465515

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Albiglutide vs Placebo: serious adverse events932 of 4,717

1,022 of 4,715

-1.9 points

-3.6 to -0.3

9,432NCT02465515

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Anesthesia Control Tower Monitoring vs Standard of Care Arm: Number of Participants With Postoperative Delirium1,502 of 4,681

1,506 of 4,711

0.1 points

-1.8 to 2.0

9,392NCT03923699

Telemedicine Control Tower for the Operating Room: Navigating Information, Care and Safety

Prioritized Clinical Decision Support vs Usual Care: deaths from any cause526 of 4,550

581 of 4,837

-0.5 points

-1.8 to 0.9

9,387NCT02451670

Reducing Cardiovascular Risk in Adults With Serious Mental Illness

Intensive Control of SBP vs Standard Control of SBP: Number of Participants With All-cause Mortality155 of 4,678

210 of 4,683

-1.2 points

-2.0 to -0.4

9,361NCT01206062

Systolic Blood Pressure Intervention Trial

Intensive Control of SBP vs Standard Control of SBP: Participants Who Developed End Stage Renal Disease12 of 4,678

8 of 4,683

0.1 points

-0.1 to 0.3

9,361NCT01206062

Systolic Blood Pressure Intervention Trial

Intensive Control of SBP vs Standard Control of SBP: Number of Participants With First Occurrence of a Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Stroke, Heart Failure (HF), or CVD Death243 of 4,678

319 of 4,683

-1.6 points

-2.6 to -0.7

9,361NCT01206062

Systolic Blood Pressure Intervention Trial

Intensive Control of SBP vs Standard Control of SBP: deaths from any cause155 of 4,678

210 of 4,683

-1.2 points

-2.0 to -0.4

9,361NCT01206062

Systolic Blood Pressure Intervention Trial

Intensive Control of SBP vs Standard Control of SBP: serious adverse events1,793 of 4,678

1,736 of 4,683

1.3 points

-0.7 to 3.2

9,361NCT01206062

Systolic Blood Pressure Intervention Trial

Liraglutide vs Placebo: serious adverse events2,320 of 4,668

2,354 of 4,672

-0.7 points

-2.7 to 1.3

9,340NCT01179048

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Eptifibatide vs Placebo: serious adverse events66 of 4,686

60 of 4,643

0.1 points

-0.4 to 0.6

9,329NCT00089895

EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)

Simvastatin Plus Ezetimibe vs Placebo: Non-hemorrhagic Stroke Among All of Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo131 of 4,650

174 of 4,620

-0.9 points

-1.7 to -0.2

9,270NCT00125593

Study of Heart and Renal Protection

Simvastatin Plus Ezetimibe vs Placebo: Key Outcome as Per Statistical Analysis Plan = Major Atherosclerotic Events Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo526 of 4,650

619 of 4,620

-2.1 points

-3.4 to -0.7

9,270NCT00125593

Study of Heart and Renal Protection

Simvastatin Plus Ezetimibe vs Placebo: Coronary or Non-coronary Revascularization Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo284 of 4,650

352 of 4,620

-1.5 points

-2.5 to -0.5

9,270NCT00125593

Study of Heart and Renal Protection

Simvastatin Plus Ezetimibe vs Placebo: Major Coronary Events Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo213 of 4,650

230 of 4,620

-0.4 points

-1.3 to 0.5

9,270NCT00125593

Study of Heart and Renal Protection

Simvastatin Plus Ezetimibe vs Placebo: Major Vascular Events Analyzed Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo701 of 4,650

814 of 4,620

-2.5 points

-4.0 to -1.0

9,270NCT00125593

Study of Heart and Renal Protection

Simvastatin Plus Ezetimibe vs Placebo: serious adverse events1,142 of 4,650

1,115 of 4,620

0.4 points

-1.3 to 2.2

9,270NCT00125593

Study of Heart and Renal Protection

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=54

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02499679-sae",
        "title": "Patients Receiving cCTA and FFRCT >0.80 vs Patients Receiving cCTA and FFRCT≤0.80: serious adverse events",
        "summary": "12 of 4737 against 43 of 4737; risk difference -0.7 points, 95% interval -1.0 to -0.4; NCT02499679, Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care",
        "record": "/library/comparisons/NCT02499679-sae",
        "nct_id": "NCT02499679",
        "kind": "serious-adverse-events",
        "participants": 9474,
        "risk_difference": {
          "value": -0.006544226303567659,
          "lower": -0.009853322436322238,
          "upper": -0.0035434019558058557
        },
        "group_1": "12 of 4,737",
        "group_2": "43 of 4,737",
        "difference": "-0.7 points",
        "interval": "-1.0 to -0.4",
        "trial_title": "Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care"
      },
      {
        "id": "NCT02465515-deaths",
        "title": "Albiglutide vs Placebo: deaths from any cause",
        "summary": "196 of 4731 against 205 of 4732; risk difference -0.2 points, 95% interval -1.0 to 0.6; NCT02465515, Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",
        "record": "/library/comparisons/NCT02465515-deaths",
        "nct_id": "NCT02465515",
        "kind": "deaths",
        "participants": 9463,
        "risk_difference": {
          "value": -0.0018931891645417795,
          "lower": -0.01004552452148738,
          "upper": 0.0062503488918827284
        },
        "group_1": "196 of 4,731",
        "group_2": "205 of 4,732",
        "difference": "-0.2 points",
        "interval": "-1.0 to 0.6",
        "trial_title": "Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=55",
  "request_id": "KR5eDFQCjW983ErK"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?